Urogen Pharma Ltd is primarily active in the pharmaceutical industry.

The main competitors of Urogen Pharma Ltd in the market include various pharmaceutical companies that specialize in the same therapeutic areas. Some notable competitors are Company A, Company B, and Company C. These companies also develop and market pharmaceutical products for similar indications as Urogen Pharma Ltd. However, Urogen Pharma Ltd distinguishes itself through its unique approach to drug development and its focus on innovation. Despite the competition, Urogen Pharma Ltd strives to maintain its position as a leading player in the market by continuously advancing its pipeline and delivering high-quality products to patients.

Urogen Pharma Ltd is a pharmaceutical company specializing in developing innovative therapies for urologic conditions. Founded in 2004, the company is headquartered in Israel. Urogen Pharma is dedicated to improving patients' lives by providing novel treatment options in the field of urology. With a focus on urothelial cancer and urinary tract infections, Urogen Pharma's research and development efforts aim to address unmet medical needs. The company has achieved significant milestones, including the approval of their first therapy, Jelmyto, by the U.S. Food and Drug Administration in 2020. Urogen Pharma continues to expand its pipeline and collaborate with renowned scientific and medical professionals to transform urologic care.

Urogen Pharma Ltd has achieved several significant milestones. The company successfully received FDA approval for its innovative drug, UGN-101, which offers a promising treatment option for patients with low-grade upper tract urothelial cancer. Urogen has also expanded its product portfolio and secured major collaborations with renowned pharmaceutical companies. In addition, the company has demonstrated strong financial performance, with consistent revenue growth and strategic investments in research and development. Urogen Pharma Ltd's dedication to innovation and commitment to improving patient outcomes have positioned the company as a leader in the pharmaceutical industry.

Urogen Pharma Ltd is primarily present in the United States, with its headquarters located in Princeton, New Jersey. The company focuses on developing innovative treatments for urological diseases and cancers. Urogen Pharma Ltd has a strong presence in various regions of the United States, including major cities like New York, Chicago, and Los Angeles. With their commitment to improving patient outcomes, Urogen Pharma Ltd continues to expand its reach and collaborate with healthcare professionals and organizations nationwide.

Urogen Pharma Ltd is a biopharmaceutical company committed to advancing innovative therapies for urological conditions. With a strong dedication to improving patients' lives, Urogen Pharma focuses on developing novel treatments that address significant unmet medical needs. The company's corporate philosophy revolves around excellence, integrity, and scientific rigor. By harnessing cutting-edge technology and expertise, Urogen Pharma strives to deliver transformative solutions to patients worldwide. With its unwavering commitment to scientific advancement and patient-centric approach, Urogen Pharma continues to drive progress in the field of urology.

Analysts currently set an average price target of 35,96 USD for the Urogen Pharma stock (median: 34,68 USD), implying −23,3 % versus the latest price. The consensus is based on 14 analyst ratings.

Urogen Pharma Analyytikkojen kursstavoitteet 2026

14 analysts currently rate the Urogen Pharma stock: 12 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Urogen Pharma to generate revenue of 322,20 M USD and earnings per share of −0,24 USD.

Urogen Pharma Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Urogen Pharma share trades at 40,06 EUR (46,80 USD).

The Urogen Pharma share (URGN) is listed on 3 stock exchanges, including: NASDAQ (URGN), Frankfurt (UR8.F), London (0XOD.L).

Urogen Pharma Ltd is a biopharmaceutical company that specializes in developing novel therapeutics for urological and oncological diseases. The company is based in the USA and has a global network of research and development partners. Urogen Pharma's business model includes several divisions, including research and development, manufacturing, and distribution of innovative drugs. The company specializes in developing drugs tailored to the needs of urological and oncological patients. The product range currently includes two preparations: Jelmyto™ and UGN-102. Jelmyto™ is the first and only intravesical chemotherapeutic for the treatment of superficial, non-muscle invasive tumors of the ureter. The treatment of ureteral tumors is difficult as they are typically challenging to reach and chemotherapy is usually ineffective for treating deep-seated tumors. Jelmyto™ works through direct intra-ureteral instillation and has proven to be highly effective in reducing tumor burden. UGN-102 is an innovative drug for the treatment of bladder cancer based on extensive research. The active ingredient is injected directly into the bladder and aims to destroy cancer cells without affecting healthy cells. UGN-102 is currently in Phase 3 clinical trials and has the potential to be a groundbreaking new treatment option for bladder cancer patients. In addition to product development, Urogen Pharma also invests in the manufacturing and distribution of its drugs. The company has agreements with leading contract manufacturing organizations for the production of its products and collaborates with some of the world's leading hospitals to distribute its products. Urogen Pharma's business model is based on ongoing development and innovation of new therapies for urological and oncological diseases. The company relies on close collaboration with leading research institutions and investments in the manufacturing and distribution of its products to achieve its vision of a better patient experience.

odotettu liikevaihto Urogen Pharma on 322,20 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Urogen Pharma on −11,69 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Urogen Pharma:n hinta-voitto-suhde (P/E) on tällä hetkellä −197,13. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Urogen Pharma-osakkeen arvostusta.

Urogen Pharma:n hinta-myynti-suhde (P/S) on tällä hetkellä 7,15. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Urogen Pharma-osakkeen arvostuskennuslukuna.

Urogen Pharma:n Eulpool-laatuscore on 3/10.

Urogen Pharma:n ISIN on IL0011407140. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Urogen Pharma:n WKN on A2DTCV. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Urogen Pharma:n ticker on URGN. Tämä pörssinoteeraus käytetään Urogen Pharma-osakkeiden kauppaan pörssissä.

Urogen Pharma maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Urogen Pharma kuuluu sektoriin 'Terveydenhuolto'.

Urogen Pharma:n osingot jaetaan valuutassa USD.